Max Rady College of Medicine

Term: Defined Daily Dose (DDD)

Printer friendly

Glossary Definition

Last Updated: 2005-11-29

Definition:

One of four measures of intensity of pharmaceutical use, defined daily dose (DDD) is the assumed average maintenance dose per day for a drug product when used for its major indication in everyday practice. It standardizes the measurement of drug utilization within and between drug entities and can be used to describe drug utilization across a population, and measure various aspects of intensity. A clinical measure can also be calculated. This is a technical unit of measurement and does not necessarily reflect the actual amount or dose used; it is also limited to solid drug forms only. DDDs are assigned per Anatomical Therapeutic Chemical (ATC) Classification 4th level by the WHO Collaborating Centre for Drug Statistics Methodology in Norway.

Related concepts 

Related terms 

Links 

References 

  • Martens PJ, Fransoo R, McKeen N, The Need to Know Team, Burland E, Jebamani L, Burchill C, De Coster C, Ekuma O, Prior H, Chateau D, Robinson R, Metge C. Patterns of Regional Mental Illness Disorder Diagnoses and Service Use in Manitoba: A Population-Based Study. Winnipeg, MB: Manitoba Centre for Health Policy, 2004. [Report] [Summary] [Additional Materials] (View)
  • Metge C, Black C, Peterson S, Kozyrskyj A, Roos NP, Bogdanovic B. Analysis of Patterns of Pharmaceutical Use in Manitoba, 1996: Key Findings - A POPULIS Project. Winnipeg, MB: Manitoba Centre for Health Policy and Evaluation, 1999. [Report] [Summary] (View)
  • Metge C, Kozyrskyj A, Dahl M, Yogendran M, Roos NP. Pharmaceuticals: Focussing on Appropriate Utilization. Winnipeg, MB: Manitoba Centre for Health Policy, 2003. [Report] [Summary] (View)
  • Metge C, Black C, Peterson S, Kozyrskyj AL. The population's use of pharmaceuticals. Med Care 1999;37(6 Suppl):JS42-JS59. [Abstract] (View)
  • Metge CJ, Blanchard JF, Peterson S, Bernstein CN. Use of pharmaceuticals by inflammatory bowel disease patients: a population-based study. Am J Gastroenterol 2001;96(12):3348-3355. [Abstract] (View)
  • Morgan SG, Kozyrskyj A, Metge C, Roos NP. Pharmaceuticals: Therapeutic interchange and pricing policies. Winnipeg, MB: Manitoba Centre for Health Policy, 2003. [Report] [Summary] (View)
  • Sketris IS, Metge C, Shevchuk Y, Comeau DG, Kephart GC, Blackburn J, MacCara M, Laturnas A. Comparison of anti-infective drug use in elderly persons in Manitoba, Nova Scotia, and Saskatchewan, Canada: relationship to drug insurance reimbursement policies. Am J Geriatr Pharmacother 2004;2(1):24-35. [Abstract] (View)

Term used in 

  • Martens P, Nickel N, Forget E, Lix L, Turner D, Prior H, Walld R, Soodeen RA, Rajotte L, Ekuma O. The Cost of Smoking: A Manitoba Study. Winnipeg, MB: Manitoba Centre for Health Policy, 2015. [Report] [Summary] [Updates and Errata] [Additional Materials] (View)
  • Martens PJ, Bartlett J, Burland E, Prior H, Burchill C, Huq S, Romphf L, Sanguins J, Carter S, Bailly A. Profile of Metis Health Status and Healthcare Utilization in Manitoba: A Population-Based Study. Winnipeg, MB: Manitoba Centre for Health Policy, 2010. [Report] [Summary] [Updates and Errata] [Additional Materials] (View)
  • Raymond C, Metge C, Alessi-Severini S, Dahl M, Schultz J, Guenette W. Pharmaceutical Use in Manitoba: Opportunities to Optimize Use. Winnipeg, MB: Manitoba Centre for Health Policy, 2010. [Report] [Summary] (View)


Request information in an accessible format

If you require access to our resources in a different format, please contact us:

We strive to provide accommodations upon request in a reasonable timeframe.

Contact us

Manitoba Centre for Health Policy
Community Health Sciences, Max Rady College of Medicine,
Rady Faculty of Health Sciences,
Room 408-727 McDermot Ave.
University of Manitoba
Winnipeg, MB R3E 3P5 Canada

204-789-3819